Daniel Wagner
Sr. Managing Director, Investments @ Connecticut Innovations
Rocky Hill, United States
Daniel Wagner is a Series A investor at Connecticut Innovations in Rocky Hill focused on Biotechnology and Health Care. Daniel Wagner joined Connecticut Innovation as Managing Director, Investments in 2018
- Total investments:
- 15
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Daniel Wagner invests in
Stages Daniel Wagner invests in
Countries Daniel Wagner invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (33%)
- Health Care 4 (27%)
- Medical 3 (20%)
- Pharmaceutical 3 (20%)
- Therapeutics 2 (13%)
Stage
- Series A 5 (33%)
- Seed 3 (20%)
- Series C 2 (13%)
- Funding Round 2 (13%)
- Series B 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $23M / May 26, 2026 | ||
| Producing an effective chemotherapy solution with a fully automated tumor-on-a-chip, pre-prescription analysis. | $1.8M / Seed / Jun 01, 2024 | ||
| Biorez is a medical device company whose aim is to apply its patented and proprietary technology comprised of PLLA, a degradable polymer, in orthopedic implant devices for regeneration and augmentation of soft tissue. In addition to the L-C Ligament®, Biorez has also developed a suite of associated products, including the biorez GRAFT™, a FDA510(k)-cleared innovative device for soft tissue augmentation of the rotator cuff in the United States. | $3.5M / Seed / Sep 14, 2020 | ||
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $12M / Series C / Jan 29, 2020 | ||
| Tangen Biosciences LLC develops medical instrument that provides rapid nucleic acid detection, with the specificity and sensitivity of polymerase chain reaction (PCR) amplification. | $9M / Series A / Jun 20, 2019 | ||
| Biorez is a medical device company whose aim is to apply its patented and proprietary technology comprised of PLLA, a degradable polymer, in orthopedic implant devices for regeneration and augmentation of soft tissue. In addition to the L-C Ligament®, Biorez has also developed a suite of associated products, including the biorez GRAFT™, a FDA510(k)-cleared innovative device for soft tissue augmentation of the rotator cuff in the United States. | $1.5M / Series C / Mar 05, 2018 | ||
| New Haven Pharmaceuticals (NHP) is a specialty pharmaceuticals company developing proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications that represent significant market opportunities. The company's novelproduct pipeline employs proprietary, oral, controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience. | $11.8M / Series B / Oct 23, 2014 | ||
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $1M / Series A / Apr 06, 2014 | ||
| Biorez is a medical device company whose aim is to apply its patented and proprietary technology comprised of PLLA, a degradable polymer, in orthopedic implant devices for regeneration and augmentation of soft tissue. In addition to the L-C Ligament®, Biorez has also developed a suite of associated products, including the biorez GRAFT™, a FDA510(k)-cleared innovative device for soft tissue augmentation of the rotator cuff in the United States. | $5M / Jan 06, 2014 | ||
| Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. | $15M / Series A / Sep 26, 2013 | ||
| See all 15 investments → | |||
Co-Investors
About Connecticut Innovations
guidance and introductions to valuable partners, Connecticut innovations enable promising businesses to thrive.
Connecticut Innovations Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alison Malloy
Managing Director, Investments
|
|||
Matthew D. Storeygard
Managing Director, Venture Capital Investments
|
|||
Dan Devine
Regenerative Medicine Research Fund Advisory Committee Member
|
|||
|
Daniel Wagner
Sr. Managing Director, Investments
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniel Wagner invest in?
Daniel Wagner invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel Wagner?
Public channels for Daniel Wagner include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel Wagner last invest?
The most recent investment recorded for Daniel Wagner closed in May 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
